Mackenzie Financial Corp Fate Therapeutics Inc Transaction History

Mackenzie Financial Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $132,209 - $268,607	-4,456 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $11,481 - $15,441	-240 Reduced 5.11%	4,456 $261,000
Q3 2021 Nov 08, 2021	BUY	$59.27 - $95.73 $113,442 - $183,227	1,914 Added 68.8%	4,696 $278,000
Q2 2021 Aug 11, 2021	BUY	$67.25 - $92.52 $187,089 - $257,390	2,782 New	2,782 $241,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $143M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.